|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.71 CAD | -3.85% |
|
-7.49% | -6.99% |
| 02-13 | Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 | CI |
| 01-09 | Bright Minds Biosciences Closes its US$175 Million Public Offering | MT |
Evolution of the Average Target: Bright Minds Biosciences Inc.
Evolution of the Target Price: Bright Minds Biosciences Inc.
Changes in Analyst Recommendations: Bright Minds Biosciences Inc.
e666f6bb9290177578.UbNW54gfLhbhYweqQY3AHvbFRbT2ChFdA-HBUSh5MAI.BOc8kMlaXnHWCH7mLeW6TMOCN4DOTlspVsz2ZR0jSTMQyiaQ0XEdI5saXg~d2adcbff18efe9121f0f25cb5fb9c5ca
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +13.91% | |||||
| +34.71% | |||||
| +36.05% | |||||
| +19.39% | |||||
| +34.98% | |||||
| +31.45% | |||||
| +18.7% | |||||
| +4.04% | |||||
| +11.04% | |||||
| +26.82% | |||||
| Average | +23.11% | |||||
| Weighted average by Cap. | +27.39% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
102.71CAD
Average target price
117.00CAD
Spread / Average Target
+13.91%
High Price Target
147.00CAD
Spread / Highest target
+43.12%
Low Price Target
80.00CAD
Spread / Lowest Target
-22.11%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| TD Cowen | |
| Chardan Research | |
| Piper Sandler | |
| HC Wainwright | |
| Cantor Fitzgerald | |
| Baird |
SellBuy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
102.71CAD
Average target price
117.00CAD
Spread / Average Target
+13.91%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DRUG Stock
- Consensus Bright Minds Biosciences Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition